Literature DB >> 16337083

Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues.

Kamalesh K Sharma1, Annika Lindqvist, Xin J Zhou, Richard J Auchus, Trevor M Penning, Stefan Andersson.   

Abstract

Aldosterone is the principal endogenous mineralocorticoid in humans and regulates salt and water homeostasis. Cortisol, the major glucocorticoid, has high affinity for the mineralocorticoid receptor; however, 11beta-hydroxysteroid dehydrogenase type 2 converts cortisol to the inactive steroid cortisone in aldosterone target cells of the kidney, thus limiting the mineralocorticoid action of cortisol. Deoxycorticosterone (DOC) binds to the mineralocorticocoid receptor with high affinity and circulates at concentrations comparable to aldosterone. Severe DOC excess as is seen in 17alpha- and 11beta-hydroxylase deficiencies causes hypertension, and moderate DOC overproduction in late pregnancy is associated with hypertension. Here, we demonstrate that DOC is inactivated by the 20-ketosteroid reductase activity of the human AKR1C3 isozyme. Immunohistochemical analyses demonstrate that AKR1C3 is expressed in the mineralocorticoid-responsive epithelial cells of the renal cortical and medullary collecting ducts, as well as the colon. Our findings suggest that AKR1C3 protects the mineralocorticoid receptor from activation by DOC in mineralocorticoid target cells of the kidney and colon, analogous to cortisol inactivation by 11beta-hydroxysteroid dehydrogenase type 2.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16337083     DOI: 10.1016/j.mce.2005.10.024

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  18 in total

Review 1.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 2.  Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes.

Authors:  Trevor M Penning; Phumvadee Wangtrakuldee; Richard J Auchus
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

3.  Detecting multiple variants associated with disease based on sequencing data of case-parent trios.

Authors:  Chan Wang; Leiming Sun; Haitao Zheng; Yue-Qing Hu
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

Review 4.  Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Authors:  Elise P Gomez-Sanchez
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

Review 5.  Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.

Authors:  Michael C Byrns; Yi Jin; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2010-11-16       Impact factor: 4.292

6.  Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.

Authors:  P Ye; T Yamashita; D M Pollock; H Sasano; W E Rainey
Journal:  Horm Metab Res       Date:  2008-09-25       Impact factor: 2.936

7.  Estrogen and progesterone metabolism in the cervix during pregnancy and parturition.

Authors:  Stefan Andersson; Debra Minjarez; Nicole P Yost; R Ann Word
Journal:  J Clin Endocrinol Metab       Date:  2008-03-25       Impact factor: 5.958

8.  Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension.

Authors:  Yiqiang Zhou; Pengcheng Luo; Hsin-Hsin Chang; Hui Huang; Tianxin Yang; Zheng Dong; Cong-Yi Wang; Mong-Heng Wang
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

9.  Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.

Authors:  Michael C Byrns; Trevor M Penning
Journal:  Chem Biol Interact       Date:  2008-11-01       Impact factor: 5.192

Review 10.  AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.

Authors:  Trevor M Penning
Journal:  Mol Cell Endocrinol       Date:  2018-09-19       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.